These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2665835)

  • 1. Functional domains in the heavy-chain region of factor XI: a high molecular weight kininogen-binding site and a substrate-binding site for factor IX.
    Baglia FA; Sinha D; Walsh PN
    Blood; 1989 Jul; 74(1):244-51. PubMed ID: 2665835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Localization of the high molecular weight kininogen binding site in the heavy chain of human factor XI to amino acids phenylalanine 56 through serine 86.
    Baglia FA; Jameson BA; Walsh PN
    J Biol Chem; 1990 Mar; 265(7):4149-54. PubMed ID: 2105959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of activation of coagulation factor XI by factor XIIa studied with monoclonal antibodies.
    Akiyama H; Sinha D; Seaman FS; Kirby EP; Walsh PN
    J Clin Invest; 1986 Dec; 78(6):1631-7. PubMed ID: 3491093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional characterization of human blood coagulation factor XIa using hybridoma antibodies.
    Sinha D; Koshy A; Seaman FS; Walsh PN
    J Biol Chem; 1985 Sep; 260(19):10714-9. PubMed ID: 3875611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of calcium ions and the heavy chain of factor XIa in the activation of human coagulation factor IX.
    Sinha D; Seaman FS; Walsh PN
    Biochemistry; 1987 Jun; 26(13):3768-75. PubMed ID: 3498513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assembly and expression of an intrinsic factor IX activator complex on the surface of cultured human endothelial cells.
    Berrettini M; Schleef RR; Heeb MJ; Hopmeier P; Griffin JH
    J Biol Chem; 1992 Oct; 267(28):19833-9. PubMed ID: 1400299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of binding of prekallikrein and Factor XI to high molecular weight kininogen and its light chain.
    Thompson RE; Mandle R; Kaplan AP
    Proc Natl Acad Sci U S A; 1979 Oct; 76(10):4862-6. PubMed ID: 291905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Murine monoclonal antibodies to human factor XI.
    Nishikado H; Komiyama Y; Masuda M; Egawa H; Murata K
    Thromb Res; 1986 Apr; 42(2):225-34. PubMed ID: 3487138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and functional characterization of the active light chain of activated human blood coagulation factor XI.
    van der Graaf F; Greengard JS; Bouma BN; Kerbiriou DM; Griffin JH
    J Biol Chem; 1983 Aug; 258(16):9669-75. PubMed ID: 6604052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen.
    Scott CF; Schapira M; James HL; Cohen AB; Colman RW
    J Clin Invest; 1982 Apr; 69(4):844-52. PubMed ID: 7076850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and chemical synthesis of a substrate-binding site for factor IX on coagulation factor XIa.
    Baglia FA; Jameson BA; Walsh PN
    J Biol Chem; 1991 Dec; 266(35):24190-7. PubMed ID: 1748688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping of functional domains of human high molecular weight and low molecular weight kininogens using murine monoclonal antibodies.
    Ishiguro H; Higashiyama S; Ohkubo I; Sasaki M
    Biochemistry; 1987 Nov; 26(22):7021-9. PubMed ID: 2447941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naturally occurring human antibodies against two distinct functional domains in the heavy chain of FXI/FXIa.
    De La Cadena RA; Baglia FA; Johnson CA; Wenk RE; Amernick R; Walsh PN; Colman RW
    Blood; 1988 Nov; 72(5):1748-54. PubMed ID: 2460161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of factor XIa activity by platelets and alpha 1-protease inhibitor.
    Walsh PN; Sinha D; Kueppers F; Seaman FS; Blankstein KB
    J Clin Invest; 1987 Dec; 80(6):1578-86. PubMed ID: 3500185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional characterization of platelet-bound factor XIa: retention of factor XIa activity on the platelet surface.
    Walsh PN; Sinha D; Koshy A; Seaman FS; Bradford H
    Blood; 1986 Jul; 68(1):225-30. PubMed ID: 3487355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High molecular weight kininogen-binding site of prekallikrein probed by monoclonal antibodies.
    Hock J; Vogel R; Linke RP; Müller-Esterl W
    J Biol Chem; 1990 Jul; 265(20):12005-11. PubMed ID: 1694851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The factor IX phospholipid-binding site is required for calcium-dependent activation of factor IX by factor XIa.
    Liebman HA; Furie BC; Furie B
    J Biol Chem; 1987 Jun; 262(16):7605-12. PubMed ID: 3108254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a factor IX binding site on the third apple domain of activated factor XI.
    Sun Y; Gailani D
    J Biol Chem; 1996 Nov; 271(46):29023-8. PubMed ID: 8910554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping of the high molecular weight kininogen binding site of prekallikrein. Evidence for a discontinuous epitope formed by distinct segments of the prekallikrein heavy chain.
    Herwald H; Jahnen-Dechent W; Alla SA; Hock J; Bouma BN; Müller-Esterl W
    J Biol Chem; 1993 Jul; 268(19):14527-35. PubMed ID: 7686159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High molecular weight kininogen protects human plasma kallikrein and factor XIa against inactivation by plasma protease inhibitors.
    Schapira M; Scott CF; Colman RW
    Trans Assoc Am Physicians; 1981; 94():190-7. PubMed ID: 6979819
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.